Remove topic bio-pharma business
article thumbnail

Liminatus Pharma enters SPAC merger deal with Iris Acquisition

Pharmaceutical Technology

Liminatus Pharma has entered a definitive business combination agreement with special purpose acquisition company (SPAC) Iris Acquisition to create a business with a pro forma enterprise value of nearly $334m. These funds are expected to back the further business growth plan of Liminatus. Free Whitepaper.

Pharma 52
article thumbnail

Imagene Profiles Cancer Biomarkers in Real Time

Medgadget

Such work requires a lot of data points and they’re working with medical centers, labs, pharma companies, and using public data to continue developing the technology. This year it is scheduled for May 16-18, 2023 in Tel Aviv, and topics range from medical robotics, to bio-convergence, to the impact of AI on biopharma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Aesthetic Medical Sales With The Lauren Brown – Medical Sales Influencer

Evolve Your Success

From her early days at Stryker to her current role as a thriving aesthetic device representative, Lauren unravels the unique blend of science, art, and business that makes this field both challenging and fulfilling. We also have another product that’s a bio stimulator. Tune in now! That takes about three months for it to kick in.

article thumbnail

New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation

pharmaphorum

Healthcare transformation has been a widely discussed topic for years, with many arguing for a more streamlined and tech- and data-driven approach to the industry that affects all people. Looking at the future, our goals are not only to support the business, but also to diversify and build something new.”.

article thumbnail

Reuters Pharma 2022 – a day one overview – part 1

pharmaphorum

The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. The onus, he said, was on pharma to listen now. Patient engagement – what history teaches us about pharma’s future evolution. Maximising potential, inspiring in pharma.

Pharma 78